DNTH News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DN

Mkt Cap

$4.04B

Volume

898.26K

Next Earnings

November 4th

Loading chart

DN

DNTHDianthus Therapeutics, Inc. Common Stock

DNTH

Pay with—

Available Balance0.00

DN

Mkt Cap

$4.17B

Volume

898.26K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dianthus Therapeutics granted equity awards to six newly-hired, non-executive employees on October 1, 2026. The inducement grants consist of non-qualified stock options to purchase 106,000 shares of common stock with an exercise price of $88.32 per share and a 10-year term, vesting 25% after one year followed by equal monthly installments over 36 months.GlobeNewswire Inc. · Oct 1, 2026

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)Dianthus Therapeutics granted equity awards to six newly-hired non-executive employees on August 3, 2026, consisting of non-qualified stock options to purchase 87,000 shares at an exercise price of $106.02 per share with a 10-year term. The grants were approved by the Compensation Committee as material inducements for employment.GlobeNewswire Inc. · Aug 3, 2026

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst SaysSanofi discontinued its Phase 3 MOBILIZE study of riliprubart for CIDP patients due to failure to meet efficacy objectives. The setback highlights trial design challenges in CIDP studies and may strengthen Argenx's Vyvgart market position, which has demonstrated successful trial execution in the same indication.Benzinga · Jun 11, 2026

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsightOver 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.GlobeNewswire Inc. · Jun 2, 2026

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock RallyCormorant Asset Management acquired 950,000 shares of Dianthus Therapeutics for approximately $55 million in Q1 2026, despite the stock already surging 350% over the past year. The clinical-stage biotech company, which develops monoclonal antibody therapies for severe autoimmune diseases, recently achieved positive Phase 3 trial results and maintains a strong $1.2 billion cash position, suggesting potential for further upside.The Motley Fool · May 17, 2026

LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and DermatomyositisNanjing Leads Biolabs and partner Dianthus Therapeutics announced that LBL-047, a bifunctional fusion protein targeting plasmacytoid dendritic cells and B cell function, has been selected for clinical development in three autoimmune indications: Sjögren's disease, systemic lupus erythematosus, and dermatomyositis. A Phase 1 study initiated in December 2025 is expected to yield results in the second half of 2026. Dianthus recently raised $719 million to support global development of the asset.GlobeNewswire Inc. · May 6, 2026

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares worth approximately $739,000 on April 9, 2026, through an option exercise and immediate sale under a Rule 10b5-1 plan. The transaction reduced his direct common stock holdings to zero, though he retains 71,776 unexercised stock options. The sale appears to be routine liquidity management rather than a strategic exit, especially given the company's recent positive phase 3 trial results for its lead candidate claseprubart.The Motley Fool · Apr 19, 2026

Dianthus Therapeutics CFO Sells $9.5 Million in StockRyan Savitz, CFO of Dianthus Therapeutics, sold 114,367 shares worth $9.49 million on March 31, 2026, exercising stock options and liquidating his entire direct common stock holdings. The sale occurred under a Rule 10b5-1 plan following the company's impressive 402% stock price gain over the past year. Savitz retains 90,399 stock options, and the company's lead candidate DNTH103 is on track for phase 3 trials mid-2026.The Motley Fool · Apr 6, 2026

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public OfferingDianthus Therapeutics announced the pricing of an upsized underwritten public offering of 7.3 million shares at $81.00 per share and pre-funded warrants, generating approximately $625 million in gross proceeds. The company plans to use the funds to advance clinical and preclinical development activities, commercial readiness, and general corporate purposes. The offering is expected to close on March 12, 2026.GlobeNewswire Inc. · Mar 11, 2026

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Dianthus Therapeutics announced a conference call and webcast scheduled for March 9, 2026 to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial evaluating claseprubart for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The clinical-stage biotech company is presenting data on its investigational therapy for severe autoimmune diseases.GlobeNewswire Inc. · Mar 8, 2026

to start trading

DN

DNTHDianthus Therapeutics, Inc. Common Stock

DNTH

Pay with—

Available Balance0.00

Your PositionYou don't own any DNTH yet.

Related Tickers

Earnings